Incyte Entered into a Clinical Trial Collaboration and Supply Agreement with Mirati to Evaluate INCB99280 and Adagrasib for KRASG12C-Mutated Solid Tumors
Shots:
- The companies collaborated to conduct the P-I/Ib trial of Incyte’s INCB99280 (PD-L1 inhibitor) + adagrasib (KRASG12C selective inhibitor) in patients with KRASG12C-mutated solid tumors
- Incyte will be responsible to initiate and sponsor the study of INCB99280 + adagrasib for KRASG12C-mutated solid tumors while Mirati will supply adagrasib
- INCB099280 showed promising clinical activity and safety & will be studied in the P-II studies as monothx. and in combination with other antitumor agents. Adagrasib is being evaluated in multiple clinical trials in combination with other anti-cancer therapies for advanced solid tumors while the registration-enabling studies are ongoing in NSCLC and colorectal cancer
Ref: Mirati| Image: Mirati
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
